夏承来;严鹏科;黄汉辉;
XIA Cheng-lai,YAN Peng-ke,HUANG Han-hui(Department of Pharmacy,the Third Affiliated Hospital,Medical College of Guangzhou,Guangzhou,Guangdong 510150,China)

• 1:广州医学院第三附属医院药剂科

摘要(Abstract)：

目的研究CCR5Δ32及CCR5 siRNA修饰的PBMC细胞对H IV-1假病毒的拮抗作用。方法将CCR5Δ32和CCR5 siRNA的基因连接到腺病毒载体上,用磷酸钙法将其转入人源性PBMC,W esternb lot检测CCR5Δ32稳定表达情况以及CCR5 siRNA对CCR5的抑制情况。构建H IV-1假病毒,检测荧光素酶报告基因的活性,判断病毒的感染情况。结果 CCR5Δ32在PBMC细胞上获得稳定表达,CCR5 siRNA抑制PBMC细胞中CCR5的表达;修饰后的PBMC细胞并不能被H IV-1假病毒感染。结论修饰后的PBMC细胞具有较好的拮抗H IV-1假病毒感染的作用。
Objective To detect the function of human peripheral blood-derived PBMCs modified by CCR5Δ32 and CCR5 siRNA to HIV-1 psedovirus.Methods The adenovirus-derived CCR5Δ32-CCR5siRNA vector was constructed.The genes were transfected into human peripheral blood-derived PBMC cells by using calcium phosphate.The HIV-1 psedovirus was constructed,and its infection was determined by testing the activity of luciferase.Results The stable expression of CCR5Δ32 in human peripheral blood-derived PBMC cells was obtained.CCR5 was inhibited by CCR5siRNA.Those modified PBMC cells could not be infected by HIV-1 pseudovirus.Conclusion Compared to normal PBMCs,the modified cells show good characteristic in resisting HIV-1 psedovirus infection.

关键词(KeyWords)： 趋化因子;人类免疫缺陷病毒;艾滋病;假病毒
CCR5;HIV-1;AIDS;psedovirus

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 夏承来;严鹏科;黄汉辉;
XIA Cheng-lai,YAN Peng-ke,HUANG Han-hui(Department of Pharmacy,the Third Affiliated Hospital,Medical College of Guangzhou,Guangzhou,Guangdong 510150,China)

Email:

DOI:

参考文献(References)：

• [1]H櫣tter G,Nowak D,Mossner M,et al.Long-term control ofHIV by CCR5 Delta32/Delta32 stem-cell transplantation[J].N Engl J Med,2009,360(7):692-698.
• [2]Kristina Allers,Gero H櫣tter,J rg Hofmann,et al.Evidencefor the cure of HIV infection by CCR5Δ32/Δ32 stem cellTransplantation[J].Blood,2010,117(10):2791-2799.
• [3]J Anderson,R Akkina Complete knockdown of CCR5 bylentiviral vector-expressed siRNAs and protection of trans-genic macrophages against HIV-1 infection[J].Gene Ther-apy,2007,14(5):1287-1297.
• [4]Heyndrickx L,Vermoesen T,Vereecken K,et al.Antiviralcompounds show enhanced activity in HIV-1 single cyclepseudovirus assays as compared to classical PBMC assays[J].J Virol Methods,2008,148(12):166-173.
• [5]Shafer RW,Schapiro JM.HIV-1 drug resistance mutations:an updated framework for the second decade of HAART[J].AIDS Rev,2008,10(2):67-84.
• [6]Sung H,Jung YS,Kang MW,et al.High frequency of drugresistance mutations in human immunodeficiency virus type1-infected Korean patients treated with HAART[J].AIDSRes Hum Retroviruses,2007,23(10):1223-1229.
• [7]Wang YM,Dyer WB,Workman C,et al.Drug resistance andviral evolution in plasma and peripheral blood cells duringstructured treatment interruption(STI)and non-interruptedHAART[J].Curr HIV Res,2007,5(2):235-250.
• [8]Hogg RS,Bangsberg DR,Lima VD,et al.Emergence ofdrug resistance is associated with an increased risk of deathamong patients first starting HAART[J].PLoS Med,2006,3(9):e356.
• [9]Chew CB,Potter SJ,Wang B,et alAssessment of drug re-sistance mutations in plasma and peripheral blood mononu-clear cells at different plasma viral loads in patients receiv-ing HAART[J].J Clin Virol,2005,33(3):206-216.
• [10]Potter SJ,Dwyer DE,Saksena NK.Differential cellulardistribution of HIV-1 drug resistance in vivo:evidence forinfection of CD8+T cells during HAART[J].Virology,2003,305(2):339-352.
• [11]Roge BT,Katzenstein TL,Nielsen HL,et al.Drug re-sistance mutations and outcome of second-line treatmentin patients with first-line protease inhibitor failure on nelfi-navir-containing HAART[J].HIV Med,2003,4(1):38-47.